Protagonist Therapeutics stock price target raised to $112 by BMO Capital
PositiveFinancial Markets

Protagonist Therapeutics has received a boost as BMO Capital has raised its stock price target to $112. This adjustment reflects growing confidence in the company's potential and could attract more investors. Such positive analyst ratings often lead to increased market interest, which is crucial for the company's growth and stability.
— Curated by the World Pulse Now AI Editorial System